Medtronic Launches Predictive MiniMed 640G Insulin Pump Outside The U.S.
This article was originally published in The Gray Sheet
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
You may also be interested in...
The United Kingdom’s National Health Service should adopt Medtronic’s MiniMed Paradigm Veo insulin pump/glucose monitor system over rival systems for patients with type 1 diabetes who experience disabling hypoglycemia, the country's National Institute for Health and Care Excellence recommends.
Medtronic makes more progress in cloded-loop glucose control and St. Jude announces results of pivotal trial of Axium neurostimulator.
Medtronic inking four diabetes deals in about a month's time is no coincidence. The company wants to transform itself from a device maker that sells mostly to type 1 diabetics, into an integrated-care company that serves the broader diabetes community, and it does not have all the capabilities it needs to accomplish that feat in house, explains Hooman Hakami, who heads Medtronic's diabetes unit.